

# Searching for New Directions in the Treatment of Oncological Diseases

**Makhmatkulova G. M.** – Student of the 509th group of the therapeutic faculty  
Scientific Supervisor: **Asatulaev Akmal Farxatovich**  
Department: Oncology  
Samarkand State Medical University, Samarkand, Uzbekistan.

**Abstract:** The prevalence of cancer is steadily increasing every year and, most likely, will continue to grow in the future, which means that malignant neoplasms need to be detected as early as possible and treated as accurately as possible.

Despite certain advances in diagnostics and treatment methods, the rate of increase in cancer incidence is steadily increasing.

Treating patients with cancer is challenging.

That is why the problem of choosing adequate treatment regimens and choosing innovative drugs in the field of oncology is relevant today.

At the moment, modern oncology of anticancer drugs has changed traditional methods for testing new anticancer drugs and assessing their effectiveness through the introduction of large multicenter randomized studies, the indications for the use of existing drugs are being expanded and new ones are being introduced.

**Key words:** oncology, innovative drugs

**Materials and methods:** The research material was literature data presented in scientific articles, textbooks, magazines

**Conclusion:** The scientific community and major pharmaceutical companies are actively working to find ways to increase the effectiveness of antitumor therapy, which implies improving existing drugs and developing innovative drugs.

In order to bring a new drug to the market, it must successfully pass all the necessary studies, during which its effectiveness will be proven, and its safety profile will be studied.

This path requires large material costs and time.

However, in cases where the presented results of early phases of clinical trials indicate high effectiveness of the drug candidate, this period may be shortened.

This is due to the fact that in the treatment of cancer, the use of effective therapy cannot be delayed, because for many patients this particular drug may be the only chance for life.

## References:

1. Crawford, Jeffrey, David C. Dale, and Gary H. Lyman. "Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management." *Cancer* 100.2 (2004): 228-237.
2. Van Straten, Demian, et al. "Oncologic photodynamic therapy: basic principles, current clinical status and future directions." *Cancers* 9.2 (2017): 19.

3. Paterlini-Brechot, Patrizia, and Naoual Linda Benali. "Circulating tumor cells (CTC) detection: clinical impact and future directions." *Cancer letters* 253.2 (2007): 180-204.